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INFORMING THE DECISION: IMPROVING GENERALIZABILITY BY 
PARAMETERIZING RELEVANT INFORMATION IN THE ECONOMIC 
EVALUATION OF TRASTUZUMAB IN EARLY BREAST CANCER
Joore MA1, Hoomans T2, Tjan-Heijnen V1, Seferina S1, Goettsch W3, Grutters J2
1Maastricht University Medical Center, Maastricht, Limburg, The Netherlands; 2Maastricht 
University, Maastricht, Limburg, The Netherlands; 3Health Insurance Council, Diemen, 
Noord-Holland, The Netherlands
OBJECTIVES: To better inform decision-makers on how practice may deviate from 
scientiﬁ c evidence, and for which factors further research is particularly worthwhile, 
through parameterizing factors that may impact the generalizability of economic 
evaluations. METHODS: We modeled the long-term cost-effectiveness of trastuzumab 
in early breast cancer. Based on a review, ﬁ ve real-world factors that could inﬂ uence 
the cost-effectiveness of trastuzumab in daily practice were identiﬁ ed: comparators, 
patient consequences, clinical practice, patient mix, and professional use. To explore 
the impact of these factors on (cost-)effectiveness, parameters were added to the model. 
Parameter values, ranges, and distributions were based on literature and expert 
opinion. Analyses were performed without (trial scope) and with real-world factors 
included (decision scope). Cost-effectiveness acceptability curves were drawn and 
value of information was analyzed. RESULTS: In the trial-scope analysis, the FinHer 
regimen dominated the other two trastuzumab regimens, and was cost-effective com-
pared to usual care (c1.845/QALY). In the decision-scope analysis, the HERA regimen 
was most effective, amounting to c50.746/QALY gained compared to FinHer. At a 
ceiling ratio of c30.000, the FinHer regimen was most likely to be cost-effective in 
both analyses. However, this probability was higher in the trial-scope analysis (98%) 
than in the decision-scope analysis (54%). Hence, the probability that in the real world 
a wrong decision is made is considerably higher than suggested in the trial-scope 
analysis. The parameter for which in the real world further research was most valuable 
was the credibility of the FinHer regimen. CONCLUSIONS: Incorporating parameters 
that improve generalizability is feasible, even in absence of evidence. Parameterizing 
the uncertainty of these parameters provides an estimation of how likely it is for each 
comparator to be cost-effective in the real world. Also, it informs decision-makers and 
researchers for which parameters further research is most valuable, for instance, in 
patient access schemes. 
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HYPOGLYCEMIA-RELATED HEALTH-CARE UTILIZATION FOLLOWING 
INITIATION OF INSULIN ASPART IN A VIAL/SYRINGE OR IN A 
PREFILLED DISPOSABLE PEN (FLEXPEN®). ANALYSIS OF REAL-WORLD 
UTILIZATION IN THE UNITED STATES
Aagren M1, Luo W2
1Novo Nordisk Inc, Princeton, NJ, USA; 2Novo Nordisk Inc, Yardley, PA, USA
OBJECTIVES: Diabetes is a chronic and progressive disease that for many patients 
requires initiation and intensiﬁ cation of insulin in order to sustain glycemic control 
and thereby lower risk of long-term complications. Insulin intensiﬁ cation, however, 
can have some negative consequences for patients in the form of increased risk of 
hypoglycemic events. This analysis asks the question to what extent the administration 
vehicle, preﬁ lled pen versus vial and syringe, has an impact on the risk of hypoglycemic 
events. METHODS: This is a retrospective database analysis comparing the incidence 
of hypoglycemia-related health-care utilization between patients that were previously 
naïve to short-acting insulin initiating the short-acting insulin analogue, insulin aspart 
(IAsp), in either a vial or in a preﬁ lled disposable pen (FlexPen®). Data were derived 
from health-care claims for individuals with employer-sponsored primary or Medicare 
supplemental insurance between 2004 and 2007. The analysis was conducted using 
logistic regression technique controlling for age, gender, diabetes type, pre-index 
hypoglycemic incidence, pre-index diabetes treatments, and daily consumption of 
IAsp. Evaluation period was 12 months. RESULTS: The cohorts consisted of 5523 
vial patients and 6065 FlexPen® patients. Mean age of the two cohorts were 53.6 
and 56.2 years (P < 0.0001) in vial and FlexPen® groups, respectively. Fifty-one 
percent and 54% (P = 0.05) of the populations were males. Generally, a larger propor-
tion the FlexPen® versus the vial cohort were already on an insulin regimen (basal or 
premix). Mean number of annual hypoglycemia-related health-care utilization inci-
dence in the period following initiation of IAsp were 1.27 and 0.87 (P < 0.0001) for 
vials and FlexPen®, respectively. After multivariate adjustment, the odds ratio of 
hypoglycemic incidence with vials versus FlexPen® was 1.36 (CI: 1.20–1.54). CON-
CLUSIONS: After controlling for potential confounders, the incidence of hypoglyce-
mia-related health-care utilization were 36% higher when initiating IAsp in a vial 
compared to initiation with FlexPen®.
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HOSPITALIZATIONS FOR SEVERE HYPOGLYCEMIAS IN PATIENTS 
WITH DIABETES MELLITUS IN SPAIN
Ramirez de Arellano A1, Lindner L2, Alvarez C3, Sanchez-Zamorano M1, De Rivas B3, 
Badia X2
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OBJECTIVES: To estimate the number of hospitalizations for severe hypoglycemia 
(SH) in patients with diabetes mellitus in Spain and assess the differences amongst 
regions. METHODS: A retrospective study was conducted using the hospital 
Minimum Basic Data Set (CMBD) which collects up to 73% of all hospitalizations in 
Spain. All hospitalization episodes of diabetic patients in which SH was the principal 
or secondary diagnosis for hospitalization during 2007 were accounted for. a SH was 
deﬁ ned as a hypoglycemic episode which requires hospitalization. RESULTS: The 
number of SH episodes as primary diagnosis was estimated at 8242 in relation to total 
discharged patients with a diagnosis of DM2 (primary and secondary) at 496,660 
patients (1.66% of total). When the number of SH as primary diagnosis is related to 
the total number of discharged patients with a diagnosis of DM2 as the primary 
diagnosis (23,343 patients), the percentage of episodes become 35.31%. The number 
of SH as a secondary diagnosis for hospitalization was estimated at 17,302 episodes: 
16,649 in patients with DM2 (96.2%) and 653 in patients with DM1 (3.8%). For 
DM2 when SH as secondary diagnosis are added to primary diagnosis, the number 
of episodes is 24,891, which means that hypoglycemia diagnosis accounts for 5.01% 
of hospitalizations for DM2 patients (496,660 patients). Catalonia shows the highest 
number of SH, with 1477 episodes as a primary diagnosis in DM2 patients (17.9% 
of total) and 3836 episodes of SH as a secondary diagnosis in DM2 patients (23.0% 
of total). CONCLUSIONS: Severe hypoglycemia represents a signiﬁ cant cause for 
hospitalization for DM2 patients in Spain: incidence of 1.66% estimated in the overall 
DM2 patients increases to 35.3% in the subpopulation of patients discharged for DM2 
as primary diagnosis. There is a great variation in the incidence of severe hypoglycemia 
between regions.
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EFFICACY AND SAFETY OF DIPEPTIDYL-PEPTIDASE 4 [DPP 4] 
INHIBITORS IN TYPE 2 DIABETES: META-ANALYSIS
Park H, Kim YA, Rascati KL
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To assess the efﬁ cacy and safety of dipeptidyl peptidase-4 (DPP-4) 
inhibitors, including saxagliptin, sitagliptin, and vildagliptin, in type 2 diabetic 
patients. METHODS: Meta-analysis was conducted for efﬁ cacy (Hemoglobin A1c and 
weight) and safety outcomes (hypoglycemia and other adverse events). Both published 
and unpublished randomized controlled trials (RCTs) for type 2 diabetic patients using 
DPP-4 inhibitors were included. RCTs were selected if criteria included a duration of 
at least 12 weeks and they compared DPP-4 inhibitors with placebo or other hypo-
glycemic medications. Two reviewers independently assessed trials for inclusion and 
extracted data. Differences were resolved by consensus. RESULTS: Of 579 potentially 
relevant articles identiﬁ ed, 118 were retrieved for detailed evaluation, and 52 met 
inclusion criteria. DPP-4 inhibitors signiﬁ cantly reduced hemoglobin A1c compared 
with placebo (weighted mean difference, −0.851% [95% conﬁ dence interval {CI}, 
−1.057% to −0.645%]) and were noninferior to other hypoglycemic agents (0.117% 
[95% CI, −0.042% to 0.276%]). DPP-4 inhibitor increased weight compared with 
placebo (0.186 kg [95% CI, 0.128 kg to 0.244 kg]), but the increase was not signiﬁ -
cantly different from other hypoglycemic agents. Also compared with placebo, DPP-4 
inhibitors had an increased risk of hypoglycemia (odd ratio [OR], 1.430 [95% CI, 
1.198–1.708]) and any adverse event (OR, 1.072 [95% CI, 1.003–1.145]). However, 
the risk of experiencing hypoglycemia or any adverse event was signiﬁ cantly lower in 
patients using DPP-4 inhibitors compared to other hypoglycemic agents (OR, 0.307 
[95% CI, 0.247–0.381]; OR, 0.828 [95% CI, 0.765–0.896], respectively). a similar 
result was also seen with serious adverse events (OR, 0.834 [95% CI, 0.699–0.996]) 
and GI adverse events (OR, 0.810 [95% CI, 0.715–0.917]) for DPP-4 inhibitors versus 
other oral antidiabetic medications. CONCLUSIONS: DPP-4 inhibitors had similar 
efﬁ cacy for hemoglobin A1c reduction and weight loss, and had a decreased risk of 
hypoglycemia and other adverse events compared with other hypoglycemic agents.
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EVENTS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH 
ORAL ANTIDIABETIC DRUGS IN CHINA
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OBJECTIVES: The study reported the utilization of oral antidiabetic drugs (OADs), 
glycemic control, hypoglycemia, and adverse events of type 2 diabetes mellitus 
(T2DM) patients with OADs therapy during their clinical visits in urban hospitals in 
China. METHODS: The study was a cross-sectional survey conducted at 75 hospitals 
in nine cities in China. There were 9577 T2DM patients with OADs therapy com-
pleted the questionnaires. The survey period was from December 3, 2008 to July 31, 
2009. Patients’ self-report on their diabetes condition and the latest health examina-
tion was used to evaluate the diabetes management situation. Descriptive statistics 
method was used for the analyses. RESULTS: A total of 51.1% of the patients were 
male, the mean age (±SD) was 59.5 ± 12.7 years, and the mean duration of disease 
(±SD) was 7.9 ± 6.3 years. The percentage of patients treated with biguanides, sulfo-
nylurea, meglitinides, glitazones, α-glucosidase inhibitors, and others (including tra-
ditional Chinese medicine) were 78.4%, 65.1%, 14.0%, 12.6%, 31.1%, and 18.1% 
respectively. Blood glucose control was inadequate, the mean HbA1c and fasting blood 
glucose were 9.1 ± 2.4% and 9.4 ± 3.4 mmol/L, respectively. Only 7.9% of the 
patients achieved the treatment target (HbA1c < 6.5%). There were 15.3% patients 
who experienced hypoglycemia episodes in the last 4 weeks, the mean hypoglycemia 
rates were 26.0/patient/year, of which major hypoglycemia rates were 7.8/patient/year, 
and nocturnal hypoglycemia rates were 6.5/patient/year. There were 60.3% OADs 
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patients who reported adverse events in the last 4 weeks, of which, 14.8% experienced 
digestive symptoms, 8.9% with skin allergies, 22.2% with blurred vision, 4.0% with 
liver and kidney damages. CONCLUSIONS: The majority of T2DM patients treated 
with OADs in China had suboptimal glycemic control. The adverse events of OADs 
treatment impose a high disease burden on patients. It underscores the urgent need 
for new therapies in the prevention and management of diabetes.
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IMPROVING PATIENT KNOWLEDGE AND CLINICAL OUTCOMES 
THROUGH A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM
Pinto SL, Howe JL, Partha G
University of Toledo, Toledo, OH, USA
OBJECTIVES: To examine the effectiveness of an employer-sponsored, pharmacist-
provided medication therapy management (MTM) program by evaluating changes in 
patient knowledge and clinical outcomes over 1 year in patients with diabetes. 
METHODS: A prospective pre–post longitudinal study. Three 10-question knowledge 
tests were developed collaboratively by an expert panel of clinical pharmacists and 
researchers, as part of the MTM program. Throughout the duration of the program, 
pharmacists administered the tests to City of Toledo employees and their dependents 
with diabetes, at baseline, 6 months and 12 months. The tests were designed to assess 
patients’ understanding of the causes, symptoms, and clinical goals associated with 
diabetes, hypertension, and hyperlipidemia. Based on the test results, pharmacists were 
able to tailor counseling sessions by educating patients based on the questions 
answered incorrectly. Clinical data were simultaneously recorded at 3-month intervals 
over 1 year, and included the following variables: A1c, systolic blood pressure (SBP), 
and diastolic blood pressure (DBP). Data were analyzed with SPSS v16.0 using descrip-
tive statistics, and Wilcoxin tests. RESULTS: One hundred and one patients enrolled 
in the MTM program. Diabetes knowledge improved for 29 patients (58.00%; P < 
0.001) after only 6 months. Hypertension test scores improved for 15 patients (65.22%; 
P < 0.01) after 1 year. Of those patients, reductions in SBP and DBP toward goal were 
seen in 11 (73.33%, P = 0.023) and 15 patients (100%, P = 0.001), respectively. Overall, 
41 patients (56.16%; P = 0.042) reduced their A1c toward goal within 3 months; 22 
patients (59.46%; P = 0.050) were able to decrease their SBP toward goal, whereas 24 
patients (64.86%; P = 0.018) reduced their DPB toward goal after 12 months in the 
program. CONCLUSIONS: This community pharmacy MTM program has effectively 
shown that consistent patient education delivered by a clinical pharmacist can have a 
positive impact on knowledge of disease for patients with diabetes while improving 
clinical outcomes concomitantly.
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PERFORMANCES OF COMORBIDITY MEASURES IN HEALTH CARE-
RELATED BEHAVIORS AND OUTCOMES IN TYPE 2 DIABETES
Ou HT, Balkrishnan R, Erickson SR, Bagozzi RP, Mukherjee B, Piette JD
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To assess and compare the predictive and discriminative performances 
of comorbidity indexes for health-care outcomes and evaluate comorbidity dimension-
ality using psychometric techniques. METHODS: The sample was type 2 diabetes in 
the Medicaid setting from 2003 to 2007. The conceptual framework was based on 
the Aday-Anderson’s Healthcare Utilization model. Four comorbidity indexes targeted 
were the Charlson Comorbidity Index, Elixhauser Index (EI), Chronic Disease Score 
(CDS), and Health-related Quality-of-Life Comorbidity Index (HRQL-CI). Three 
types of outcomes were health-care behaviors, including physician treatment adher-
ence and patient medication adherence, utilization and expenditures. Multiple regres-
sion analyses assessed the predictive performance of comorbidity index. The c statistic 
(the area under the receiver operator curve) evaluated discriminative validity of the 
comorbidity index. Conﬁ rmatory factor analysis identiﬁ ed comorbidity dimensional-
ity. The SASTM, STATATM, and LISRELTM statistical software were utilized. RESULTS: 
A total of 9832 patients were ﬁ nally included, with mean age of approximate 45 years 
and the majority of them was female (73%) and White (52%). The CDS demonstrated 
the best performance in predicting physician treatment adherence and discriminating 
medication adherence behavior. The CDS and HRQL-CI mental aspect index had 
better predictive validity for medication adherence and similar discrimination for 
physician treatment adherence. Diagnosis-driven indexes (e.g., EI) had better perfor-
mances for health-care utilization and expenditures outcomes compared to medica-
tion-based index (CDS). A 7-factor pattern/dimensionality was noticed and it provided 
best model ﬁ t and predictive performance across different health-care outcomes. 
Individual comorbidity dimensions demonstrated differential impacts for a given 
outcome. CONCLUSIONS: The CDS and HRQL-CI mental aspect index served as 
better risk adjustment tools for studying health-care behaviors. Diagnosis-driven 
indexes remained the ﬁ rst choice for health-care utilization and expenditures data. 
Comorbidity index which accounts for comorbidity dimensionality provided better 
risk adjustment and insightful knowledge regarding the impacts of different features 
of comorbidities in predicting patient outcomes.
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PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL 
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Hammer H1, Dippel FW2, Kostev K3, Fuchs S4, Kotowa W4
1Dr. Med. Harm Hammer, Bremen, Germany; 2Sanoﬁ -Aventis Deutschland GmbH, Berlin, 
Germany; 3IMS Health GmbH & Co. OHG, Frankfurt am Main, Germany; 4IMS Health 
GmbH & Co. OHG, Nürnberg, Germany
OBJECTIVES: To assess the predictors for the initiation of a basal-supported oral 
therapy (BOT) in type 2 diabetics (T2D) under real-life conditions in Germany. 
METHODS: This historical cohort study included T2D who started an oral antidia-
betic drug (OAD) treatment between January 1995 and June 2006 and whose records 
were eligible at least 12 months before and 36 months after OAD initiation. Data 
were extracted from a representative real-life database (IMS® Disease Analyzer). BOT 
initiation was deﬁ ned according to the ATC code of the European Pharmaceutical 
Market Research Association, with A10C2 (NPH insulin) and A10C5 (long-acting 
insulin analogues) prescribed additionally to OADs. The time-dependent rate of T2D 
starting BOT was calculated by use of the Kaplan–Meier method. Univariate and 
multivariate Cox regression analyses were applied to identify predictive associated 
factors. RESULTS: A total of 9028 T2D on initial OAD therapy were included, of 
whom 1450 patients have been switched to BOT during the observational period. The 
probability of BOT initiation was associated with poor metabolic control, midlife age, 
and OAD therapy before insulinization. The combined Cox regression analysis identi-
ﬁ ed three groups of particular importance: group I (hazard ratio [HR] = 2.72; P < 
0.001): HbA1c > 8%, age 51–60 years, and sulfonylurea (SU), alpha-glucosidase 
inhibitor (AGI), or glinide (GLI) as last OAD prescribed, group II (HR = 2.62; P = 
0.032): HbA1c > 8%, age ≤ 50 and pretreatment with at least three OADs, and group 
III (HR = 2.10; P = 0.019): HbA1c > 8%, pretreatment with a combination of at least 
three OADs and SU, AGI, or GLI as last OAD prescribed. The HbA1c threshold of 
7.5% led to comparable results, although only group I reached signiﬁ cance. CON-
CLUSIONS: The probability of BOT initiation for T2D under real-life conditions in 
Germany was associated with poor metabolic control, midlife age, and pretreatment 
with SU, AGI, or GLI. This knowledge may help to identify patients who might beneﬁ t 
from an early initiation of BOT.
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FACTORS ASSOCIATED WITH THE CHOICE OF FIRST INJETABLE 
THERAPY AND 6-MONTH TREATMENT OUTCOMES IN PATIENTS 
WITH TYPE 2 DIABETES: DATA FROM THE CHOICE STUDY IN 
GERMANY
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OBJECTIVES: CHOICE is an ongoing prospective, multicountry observational study 
designed to evaluate time to signiﬁ cant treatment change among adults with type 2 
diabetes (T2D) initiating injectable therapy in routine practice, and describing baseline 
characteristics, clinical outcomes, and common adverse events over 24 months. Results 
presented are from 6-month data analyses of the German sample. METHODS: Data 
were collected at initiation of exenatide or insulin, and 3 and 6 months thereafter. 
RESULTS: In Germany, 848 patients (394 exenatide, 454 insulin) were enrolled. 
Multivariate logistic regression indicated that high BMI, hypoglycemia, and high tri-
glyceride levels were associated with exenatide initiation, while increased age, high 
blood glucose levels, and increased frequency of blood glucose monitoring were associ-
ated with insulin initiation. Signiﬁ cant treatment changes were made in 20.7% of 
exenatide-treated and 29.7% of insulin-treated patients; corresponding discontinua-
tion rates of initiated injectable therapy were 15.5% and 4.1%. At 6 months, mean 
(SD) HbA1c change from baseline was −0.8% (1.4%) in the exenatide cohort (baseline 
8.2%) and −1.6% (1.7%) in the insulin cohort (baseline 8.8%). 21.5% of patients 
initiating exenatide achieved an HbA1c of <6.5% and 42.5% of <7.0%. Corresponding 
values for patients initiating insulin were 17.7% and 41.7%, respectively. Mean body 
weight changes were −3.7 kg in the exenatide cohort and +0.9 kg in the insulin cohort. 
Gastrointestinal symptoms and hypoglycemic episodes were reported by 19.7% and 
2.3% of patients in the exenatide cohort, respectively, and 2.5% and 11.3% of 
patients in the insulin cohort. CONCLUSIONS: Differences between German patients 
who initiated insulin and exenatide appear to reﬂ ect recommendations of the German 
Diabetes Association and the German health-care authorities, with exenatide favored 
when weight is high and hypoglycemia is experienced on oral therapy and HbA1c being 
only modestly raised. Treatment outcomes were consistent with results of clinical trials 
and both are important components of T2D care.
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LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY 
VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 
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OBJECTIVES: This analysis aimed to determine the long-term incremental difference 
in clinical outcomes for exenatide once-weekly (EQW) compared with insulin glargine. 
